Mild cognitive impairment: To treat or not to treat

  • Howard S. Kirshner


Mild cognitive impairment (MCI) refers to memory deficits in excess of normal aging, but not sufficient for the diagnosis of Alzheimer’s disease (AD). In general, patients with MCI are not disabled and have no other obvious cognitive deficits other than memory. Many studies have shown that patients with MCI are more likely to progress to AD than age-matched controls. Drug therapy to prevent or delay deterioration in patients with MCI has been tested only very recently. The results of three clinical trials are discussed. One of two trials with donepizil suggests that donepizil may delay onset of AD, but the effect is modest and the side effects are problematic. Galantamine appeared to be associated with excess deaths, and vitamin E was not effective. No medications are currently indicated for the prevention of dementia in patients with MCI.

References and Recommended Reading

  1. 1.
    Kral VA: Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962, 86:257–260.PubMedGoogle Scholar
  2. 2.
    Crook T, Bartus RT, Ferris SH, et al.: Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change—report of a National Institute of Mental Health work group. Dev Neuropsychol 1986, 2:261–276.CrossRefGoogle Scholar
  3. 3.
    Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999, 56:303–308.PubMedCrossRefGoogle Scholar
  4. 4.
    Petersen RC, Stevens JC, Ganguli M, et al.: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133–1142. Important reference.PubMedGoogle Scholar
  5. 5.
    Winblad B, Palmer K, Kivipelto M, et al.: Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med 2004, 256:240–246.PubMedCrossRefGoogle Scholar
  6. 6.
    Morris JC, Storandt M, Miller JP, et al.: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001, 58:397–405.PubMedCrossRefGoogle Scholar
  7. 7.
    Bozoki A, Giordani B, Heidebrink JL, et al.: Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001, 58:411–416.PubMedCrossRefGoogle Scholar
  8. 8.
    Albert MS, Moss MB, Tanzi R, Jones K: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001, 7:631–639.PubMedCrossRefGoogle Scholar
  9. 9.
    Tierney MC, Szalai JP, Snow WG, et al.: A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996, 46:149–154.PubMedGoogle Scholar
  10. 10.
    Okamura N, Arai H, Maruyama M, et al.: Combined analysis of CSF tau levels and iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer’s disease. Am J Psychiatry 2002, 159:474–476.PubMedCrossRefGoogle Scholar
  11. 11.
    Jack CR, Petersen RC, Xu YC, et al.: Prediction of AD with MRIbased hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397–1403.PubMedGoogle Scholar
  12. 12.
    Small SA, Perera GM, DelaPaz R, et al.: Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Ann Neurol 1999, 45:466–472.PubMedCrossRefGoogle Scholar
  13. 13.
    Dickerson BC, Salat DH, Bates JF, et al.: Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004, 56:27–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Dubois B, Albert ML: Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol 2004, 3:246–248.PubMedCrossRefGoogle Scholar
  15. 15.
    Cummings JL: Alzheimer’s disease. N Engl J Med 2004, 351:56–67. Important reference.PubMedCrossRefGoogle Scholar
  16. 16.
    Salloway S, Ferris S, Kluger A, et al.: Efficacy of donepizil in mild cognitive impairment. A randomized placebocontrolled trial. Neurology 2004, 63:651–657.PubMedGoogle Scholar
  17. 17.
    Petersen RC, Thomas RG, Grundman M, et al.: Vitamin E and donepizil for the treatment of mild cognitive impairment. New Engl J Med 2005, 352:2379–2388. Important reference.PubMedCrossRefGoogle Scholar
  18. 18.
    Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997, 336:1216–1222.PubMedCrossRefGoogle Scholar
  19. 19.
    Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Int Med 2005, 142:37–46.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • Howard S. Kirshner
    • 1
  1. 1.Department of Neurology, Stroke DivisionVanderbilt University School of MedicineNashvilleUSA

Personalised recommendations